Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics

Karoline Krane-Gartiser; Leif Breum; Charlotte Glümrr; Allan Linneberg; Maiken Madsen; Anne Køster; Peter W Jepsen; Anders Fink-Jensen

doi:10.3109/08039488.2011.565799

Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics

Karoline Krane-Gartiser, Leif Breum, Charlotte Glümrr, Allan Linneberg, Maiken Madsen, Anne Køster, Peter W Jepsen, Anders Fink-Jensen

30 Citations (Scopus)

Abstract

Background: The incidence of the metabolic syndrome, a major risk factor for diabetes and cardiovascular disease, is increasing worldwide and is suggested to be higher among psychiatric patients, especially those on antipsychotic treatment. Aims: To assess the prevalence of the metabolic syndrome in Danish psychiatric outpatients and compare it with the general population. Methods: In a cross-sectional, observational study in 200708, 170 Danish outpatients on antipsychotic drug treatment were monitored for the prevalence of the metabolic syndrome based on the International Diabetes Federation (IDF) definition and compared with a general population group of 3303 randomly selected Danes. Results: Of the antipsychotic-treated patients 48.2% fulfilled the IDF criteria for the metabolic syndrome, compared with 29.6% of the general population. The antipsychotic-treated patients had higher rates of increased waist circumference, triglyceride and glucose levels, and lower high-density lipoprotein cholesterol. Compared with the general population, the odds ratio (OR) of the metabolic syndrome among antipsychotic-treated patients was 2.2. After adjustment for age and sex, the OR increased to 2.7. In the antipsychotic-treated group, statistically different rates of the metabolic syndrome for patients in monopharmacy vs. polypharmacy, and for patients in monotherapy with first-generation vs. second-generation antipsychotics, could not be found. Conclusion: The metabolic syndrome is highly prevalent among a Danish outpatient population treated with antipsychotics compared with the general population. Monitoring of lipid and glucose levels, blood pressure and waist circumference before start-up and during treatment with antipsychotic medication is of pivotal importance in order to prevent diabetes and cardiovascular disease in this patient population.

Original language	English
Journal	Nordic Journal of Psychiatry
Volume	65
Issue number	5
Pages (from-to)	345-52
Number of pages	8
ISSN	0803-9488
DOIs	https://doi.org/10.3109/08039488.2011.565799
Publication status	Published - Oct 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/08039488.2011.565799

Cite this

@article{b33f1372f9bb4190891525d38beb0f7e,

title = "Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics",

abstract = "Background: The incidence of the metabolic syndrome, a major risk factor for diabetes and cardiovascular disease, is increasing worldwide and is suggested to be higher among psychiatric patients, especially those on antipsychotic treatment. Aims: To assess the prevalence of the metabolic syndrome in Danish psychiatric outpatients and compare it with the general population. Methods: In a cross-sectional, observational study in 200708, 170 Danish outpatients on antipsychotic drug treatment were monitored for the prevalence of the metabolic syndrome based on the International Diabetes Federation (IDF) definition and compared with a general population group of 3303 randomly selected Danes. Results: Of the antipsychotic-treated patients 48.2% fulfilled the IDF criteria for the metabolic syndrome, compared with 29.6% of the general population. The antipsychotic-treated patients had higher rates of increased waist circumference, triglyceride and glucose levels, and lower high-density lipoprotein cholesterol. Compared with the general population, the odds ratio (OR) of the metabolic syndrome among antipsychotic-treated patients was 2.2. After adjustment for age and sex, the OR increased to 2.7. In the antipsychotic-treated group, statistically different rates of the metabolic syndrome for patients in monopharmacy vs. polypharmacy, and for patients in monotherapy with first-generation vs. second-generation antipsychotics, could not be found. Conclusion: The metabolic syndrome is highly prevalent among a Danish outpatient population treated with antipsychotics compared with the general population. Monitoring of lipid and glucose levels, blood pressure and waist circumference before start-up and during treatment with antipsychotic medication is of pivotal importance in order to prevent diabetes and cardiovascular disease in this patient population.",

author = "Karoline Krane-Gartiser and Leif Breum and Charlotte Gl{\"u}mrr and Allan Linneberg and Maiken Madsen and Anne K{\o}ster and Jepsen, {Peter W} and Anders Fink-Jensen",

year = "2011",

month = oct,

doi = "10.3109/08039488.2011.565799",

language = "English",

volume = "65",

pages = "345--52",

journal = "Nordisk Psykiatrisk Tidsskrift",

issn = "0803-9496",

publisher = "Taylor & Francis",

number = "5",

}

TY - JOUR

T1 - Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics

AU - Krane-Gartiser, Karoline

AU - Breum, Leif

AU - Glümrr, Charlotte

AU - Linneberg, Allan

AU - Madsen, Maiken

AU - Køster, Anne

AU - Jepsen, Peter W

AU - Fink-Jensen, Anders

PY - 2011/10

Y1 - 2011/10

N2 - Background: The incidence of the metabolic syndrome, a major risk factor for diabetes and cardiovascular disease, is increasing worldwide and is suggested to be higher among psychiatric patients, especially those on antipsychotic treatment. Aims: To assess the prevalence of the metabolic syndrome in Danish psychiatric outpatients and compare it with the general population. Methods: In a cross-sectional, observational study in 200708, 170 Danish outpatients on antipsychotic drug treatment were monitored for the prevalence of the metabolic syndrome based on the International Diabetes Federation (IDF) definition and compared with a general population group of 3303 randomly selected Danes. Results: Of the antipsychotic-treated patients 48.2% fulfilled the IDF criteria for the metabolic syndrome, compared with 29.6% of the general population. The antipsychotic-treated patients had higher rates of increased waist circumference, triglyceride and glucose levels, and lower high-density lipoprotein cholesterol. Compared with the general population, the odds ratio (OR) of the metabolic syndrome among antipsychotic-treated patients was 2.2. After adjustment for age and sex, the OR increased to 2.7. In the antipsychotic-treated group, statistically different rates of the metabolic syndrome for patients in monopharmacy vs. polypharmacy, and for patients in monotherapy with first-generation vs. second-generation antipsychotics, could not be found. Conclusion: The metabolic syndrome is highly prevalent among a Danish outpatient population treated with antipsychotics compared with the general population. Monitoring of lipid and glucose levels, blood pressure and waist circumference before start-up and during treatment with antipsychotic medication is of pivotal importance in order to prevent diabetes and cardiovascular disease in this patient population.

AB - Background: The incidence of the metabolic syndrome, a major risk factor for diabetes and cardiovascular disease, is increasing worldwide and is suggested to be higher among psychiatric patients, especially those on antipsychotic treatment. Aims: To assess the prevalence of the metabolic syndrome in Danish psychiatric outpatients and compare it with the general population. Methods: In a cross-sectional, observational study in 200708, 170 Danish outpatients on antipsychotic drug treatment were monitored for the prevalence of the metabolic syndrome based on the International Diabetes Federation (IDF) definition and compared with a general population group of 3303 randomly selected Danes. Results: Of the antipsychotic-treated patients 48.2% fulfilled the IDF criteria for the metabolic syndrome, compared with 29.6% of the general population. The antipsychotic-treated patients had higher rates of increased waist circumference, triglyceride and glucose levels, and lower high-density lipoprotein cholesterol. Compared with the general population, the odds ratio (OR) of the metabolic syndrome among antipsychotic-treated patients was 2.2. After adjustment for age and sex, the OR increased to 2.7. In the antipsychotic-treated group, statistically different rates of the metabolic syndrome for patients in monopharmacy vs. polypharmacy, and for patients in monotherapy with first-generation vs. second-generation antipsychotics, could not be found. Conclusion: The metabolic syndrome is highly prevalent among a Danish outpatient population treated with antipsychotics compared with the general population. Monitoring of lipid and glucose levels, blood pressure and waist circumference before start-up and during treatment with antipsychotic medication is of pivotal importance in order to prevent diabetes and cardiovascular disease in this patient population.

U2 - 10.3109/08039488.2011.565799

DO - 10.3109/08039488.2011.565799

M3 - Journal article

SN - 0803-9496

VL - 65

SP - 345

EP - 352

JO - Nordisk Psykiatrisk Tidsskrift

JF - Nordisk Psykiatrisk Tidsskrift

IS - 5

ER -

Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this